Frailty, Medication Adherence, and Glycemic Control in Patients with Type 2 Diabetes: A Cross-Sectional Study Among Metforminand Non-Metformin-Exposed Groups
, 2, 3
Abstract
Objective: Type 2 diabetes (T2D) is a non-communicable disease that contributes to frailty. Metformin is a widely used medication for managing blood sugar, and it may help reduce frailty. This study aimed to investigate the relationships between frailty, medication adherence, and glycemic control in metformin-exposed (ME) and non-metformin-exposed (NME) patients with T2D. Materials and methods: This prospective cross-sectional study was conducted to assess frailty and medication adherence in patients with T2D divided into ME and NME groups using Fried’s Frailty Assessment and the medication adherence questionnaire, respectively. Data were summarized using descriptive statistics, and Spearman’s Rank Correlation Coefficient was used to associate frailty and medication adherence. Results: A total of 126 patients with T2D were enrolled. More of the ME group (16 persons [19.0%]) were nonfrail than in the NME group (2 [4.8%]). More of the ME group (18 [21.4%]) had high adherence compared to the NME group (8 [19.0%]). More of the patients in the ME group (11 [13.1%]) had HbA1c < 6.5% than in the NME group (4 [9.5%]). There was no significant correlation between medication adherence and frailty, neither in overall patients (p = 0.313) nor between the groups of ME (p = 0.547) and NME (p = 0.442). A significant correlation between frailty scores and glycemic control was observed in the overall patients (p = 0.045), but significance was not found within the ME (p = 0.236) and NME groups 0.062. Conclusions: There is correlation between frailty and glycemic control among patients with T2D. Metformin treatment was linked to a lower frailty risk, underscoring
the need for personalized diabetes management.
Keywords: frailtyHbA1cmedication adherencemetformin
References
- Hua F. New insights into diabetes mellitus and its complications: a narrative review. Ann Transl Med. 2020; 8(24): 1689.
- Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271–281.
- Chaudhary RK, Philip MJ, Santhosh A, et al. Health economics and effectiveness analysis of generic anti-diabetic medication from jan aushadhi: An ambispective study in community pharmacy. Diabetes Metab Syndr. 2021; 15(6): 102303.
- Tel BA, Bilgin S, Kurtkulagi O, et al. Frailty in Diabetic Subjects during COVID-19 and Its Association with HbA1c, Mean Platelet Volume and Monocyte/Lymphocyte Ratio. Clinical Diabetology. 2022; 11(2): 119–126.
- Espinoza SE, Musi N, Wang CP, et al. Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes. J Gerontol A Biol Sci Med Sci. 2020; 75(1): 102–109.
- Arévalo Lorido JC, Carretero Gomez J, Vazquez Rodriguez P, et al. Glycemic control and prescription profiles in internal medicine inpatients: The role of frailty. Eur J Intern Med. 2024; 121: 103–108.
- Walker EA, Gonzalez JS, Tripputi MT, et al. DPP Research Group. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020; 8(1).
- Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10: 1299–1307.
- Sahoo J, Mohanty S, Kundu A, et al. Medication Adherence Among Patients of Type II Diabetes Mellitus and Its Associated Risk Factors: A Cross-Sectional Study in a Tertiary Care Hospital of Eastern India. Cureus. 2022; 14(12): e33074.
- Dalvi T, Kalghatgi S. A 2023 Update of Kuppuswamy Socioeconomic Status Classification Scale for the Indian Population. Journal of Indian Association of Public Health Dentistry. 2023; 21(3): 282–283.
- ICMR guidelines for management of Type 2 Diabetes 2018. https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf (11.01.2025).
- Al-Ali SA, AlJabr QM, Alramadhan ZT, et al. Screening of Diabetic Patients for Frailty with the Frail Scale: A Comparison with the Fried's Phenotype Criteria in Saudi Arabia. International Journal of Diabetes and Clinical Research. 2021; 8(4).
- Sadakathulla I, Mateti UV, Kellarai A, et al. Adhering to antihypertensive treatment is vitally important. Salud(i)Ciencia. 2019; 23: 314–324.
- Liu P, Pan Y, Song Yu, et al. Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes. Eur J Med Res. 2023; 28(1): 65.
- Bonikowska I, Szwamel K, Uchmanowicz I. Adherence to Medication in Older Adults with Type 2 Diabetes Living in Lubuskie Voivodeship in Poland: Association with Frailty Syndrome. J Clin Med. 2022; 11(6).
- Abd Ghafar MZ, O'Donovan M, Sezgin D, et al. Frailty and diabetes in older adults: Overview of current controversies and challenges in clinical practice. Front Clin Diabetes Healthc. 2022; 3: 895313.
- Tang Z, Shen C, Tong W, et al. Frailty in Community-Dwelling Adults Aged 40 Years and over with Type 2 Diabetes: Association with Self-Management Behaviors. Int J Environ Res Public Health. 2022; 19(15).
- Pradeepa R, Shreya L, Anjana RM, et al. Sex-Based Differences in Clinical Profile and Complications among Individuals with Type 2 Diabetes Seen at a Private Tertiary Diabetes Care Centre in India. Healthcare (Basel). 2023; 11(11).
- Prasad M, Kumar V. Impact of Socio–Economic, Health and Patient Related Factors on Medication Adherence in Patients with Hypertension and Type II Diabetes. Journal of Pharmaceutical Research International. 2021: 327–338.
- Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm. 2014; 5(3): 79–83.
- Baskaran D, Aparicio-Ugarriza R, Ferri-Guerra J, et al. Is There an Association Between Metformin Exposure and Frailty? Gerontol Geriatr Med. 2020; 6: 2333721420924956.
- Sumantri S, Setiati S, Purnamasari D, et al. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes. Acta Med Indones. 2014; 46(3): 183–188.
- Hazuda HP, Pan Q, Florez H, et al. Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study. The Journals of Gerontology: Series A. 2021; 76(5): 929–936.
- Syafhan NF, Donnelly R, Harper R, et al. Adherence to metformin in adults with type 2 diabetes: a combined method approach. J Pharm Policy Pract. 2022; 15(1): 61.
- Lee DS, Lee H. Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr. 2022; 14(1): 12.
- McGovern A, Tippu Z, Hinton W, et al. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20(4): 1040–1043.
- Wang A, Wan J, Zhu L, et al. Frailty and medication adherence among older adult patients with hypertension: a moderated mediation model. Front Public Health. 2023; 11: 1283416.
- Qiao X, Tian X, Liu Na, et al. The association between frailty and medication adherence among community-dwelling older adults with chronic diseases: Medication beliefs acting as mediators. Patient Educ Couns. 2020 [Epub ahead of print].
- Nishimura R, Taniguchi M, Takeshima T, et al. Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Adv Ther. 2022; 39(1): 632–654.
- Kulkarni P, Babu PK, Vanmathi A, et al. Relationship between Frailty, Glycemic Control, and Nutritional Status among the Elderly with Diabetes Mellitus Residing in an Urban Community of Mysuru. J Midlife Health. 2022; 13(4): 294–299.
- Yanagita I, Fujihara Y, Eda T, et al. Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients. J Diabetes Investig. 2018; 9(2): 419–425.